


ARCTURUS THERAPEUTICS (NASDAQ: ARCT) is a global messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics.


LUNAR® Lipid Nanoparticle (LNP) Delivery Technology

Proprietary, Biodegradable, Optimized for Each Cell Type


LUNAR interacts with cell membrane




mRNA release



LUNAR internalized inside endosome



mRNA translated into protein of interest




Pipeline of Arcturus-Owned mRNA Therapeutic Candidates

Franchise	Candidate	Funded By	Indication	Global Prevalence	Stage
Hepatic	LUNAR-OTC (ARCT-810)	ARCTURUS THERAPEUTICS	Ornithine Transcarbamylase Deficiency	> 10,000	Phase 2
Respiratory	LUNAR-CF (ARCT-032)	CYSTIC FIBROSIS FOUNDATION	Cystic Fibrosis	85,000-100,000	Phase 2

Pipeline of Partnered mRNA Therapeutics and Vaccines

Franchise	Candidate	Partner	Indication	Stage
Vaccine	KOSTAIVE® (ARCT-154) Monovalent: JN.1	CSL	COVID-19	Approved (JP) MAA Filed (EU)
	KOSTAIVE® Bivalent (ARCT-2301) Bivalent: Ancestral/Omicron BA.4/5	CSL	COVID-19	Phase 3
	KOSTAIVE® XBB.1.5 (ARCT-2303) Monovalent: XBB.1.5	CSL	COVID-19	Phase 3
	LUNAR®-FLU (ARCT-2138) Quadrivalent	CSL	Seasonal Influenza	Phase 1
	LUNAR®-FLU (Pandemic)	BARDA	Pandemic Influenza	Pre-clinical

SCAN TO LEARN MORE ABOUT OUR PROGRAMS AND PIPELINE.



Arcturus Therapeutics

www.ArcturusRx.com

Arcturus Therapeutics

ClinicalTrials@ArcturusRx.com

@ArcturusRx